ImmuneOncia Therapeutics, Inc.
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
424870 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 탑실로35번길 25, 용인시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
ImmuneOncia Therapeutics, Inc. is a clinical-stage, immuno-oncology-centric biopharmaceutical company dedicated to developing cutting-edge immunotherapies for cancer treatment. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company leverages expertise in drug development and antibody engineering. ImmuneOncia's pipeline focuses on developing immune checkpoint inhibitors targeting T cells and macrophages. Its portfolio includes IMC-001, its lead candidate, and IMC-002, a fully human anti-CD47 monoclonal antibody for various cancers.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ImmuneOncia Therapeutics, Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all ImmuneOncia Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ImmuneOncia Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
